NasdaqGS:ALMSPharmaceuticals
Assessing Alumis (ALMS) Valuation After Successful Phase III Results For Envudeucitinib
Alumis (ALMS) is back in focus after reporting successful Phase III results for its TYK2 inhibitor, envudeucitinib, in moderate to severe plaque psoriasis. This clinical milestone has prompted fresh attention from Wall Street research desks.
See our latest analysis for Alumis.
Despite a one-day share price return of negative 8.68% leaving Alumis at US$24.51, the 30-day and year-to-date share price returns of 173.70% and a 1-year total shareholder return of 227.67% suggest momentum has been...